Cardiogen
Also known as: Cardiogen peptide, T-32 (related peptide mentioned in same study)
Short bioregulatory peptide
What it is
Cardiogen is a short peptide studied in laboratory settings for its effects on aging cells, particularly in prostate and cardiovascular tissue. Research is limited to cell cultures and early animal work, with very little published evidence. No FDA-approved use; considered an early-stage research compound.
The scientific side
Only one abstract in the reviewed literature directly mentions Cardiogen by name. PMID 20586252 reports that cardiogen (alongside peptides T-32 and T-38) was studied for its effect on the expression of signaling factors of fibroblast differentiation in human prostate gland cell cultures. In aging prostate fibroblast cultures, the peptide demonstrated the ability to enhance the expression of CXCL12, WEDC1, and ghrelin — markers whose synthesis was significantly reduced in senescent cultures. No mechanism of action in cardiac tissue, no receptor target, and no cardiac-specific pharmacology are described in any of the provided abstracts.
Class: Short bioregulatory peptide
Administration & storage
- Cautions
- No human pharmacokinetic or safety data for Cardiogen are present in the reviewed literature — clinical safety profile is entirely unknown.,No animal toxicology or dose-ranging studies for Cardiogen are described in any reviewed abstract.,The sole abstract mentioning Cardiogen describes only in vitro cell culture work; no administration route or dose for living subjects is reported.,Sterile technique is essential for any injectable peptide preparation to prevent contamination (general harm-reduction principle).
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Enhancement of signaling factor expression in aging human prostate fibroblast cultures (in vitro) In vitro only
- Cardiogen (alongside peptides T-32 and T-38) enhanced expression of CXCL12, WEDC1, and ghrelin in aging human prostate fibroblast cultures. Expression of these factors in older cultures (after 7 passages) under peptide action tended to exceed even young culture controls (after 1 passage). T-38 was noted as the most act PMID 20586252 Kheĭfets OV et al. Advances in gerontology (2010)
Protocol
No community dose for Cardiogen on record yet.
All studies (1)
- PMID 20586252 In vitro only
Enhancement of signaling factor expression in aging human prostate fibroblast cultures (in vitro)
Frequently asked
What is Cardiogen and what does it do?
Cardiogen is a short bioregulatory peptide studied in one in vitro experiment. In that study, it enhanced the expression of signaling factors (CXCL12, WEDC1, and ghrelin) in aging human prostate fibroblast cultures. No human or animal in vivo studies appear in the reviewed literature, and no cardiac-specific mechanism has been described in these abstracts.
What dose of Cardiogen should I use?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: The only abstract in the reviewed literature mentioning Cardiogen is an in vitro cell culture study and does not report any dose, concentration, or route of administration suitable for human use.
Is Cardiogen safe to inject?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. No human or animal safety data for Cardiogen appear in the reviewed abstracts.
Is Cardiogen FDA-approved?
The reviewed literature does not state any regulatory status for Cardiogen with the US FDA, Health Canada, or WADA. This requires manual verification with the relevant regulatory authority.
Can I stack Cardiogen with other peptides?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Cardiogen has only been described in one in vitro study; no human stacking or combination data exist in the reviewed literature.
What conditions is Cardiogen used for?
Based on the reviewed literature, Cardiogen has only been studied in one in vitro experiment examining its effect on aging human prostate fibroblast signaling factors. No clinical indications or approved uses appear in the reviewed abstracts.
Where can I buy Cardiogen?
I don't recommend vendors or sources. Please consult a licensed provider.
Does Cardiogen help with heart conditions?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. Despite the name, none of the reviewed abstracts report any cardiac indication or cardiac mechanism of action for Cardiogen.
What are the side effects of Cardiogen?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. No safety or adverse effect data for Cardiogen appear in any of the reviewed abstracts.
How should I reconstitute or store Cardiogen?
I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly. None of the reviewed abstracts describe reconstitution, storage, or handling conditions for Cardiogen.